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application of direct measurements of change in cartilage on MRI. The
design of MRI-based efﬁcacy studies includes decisions on sample size,
based on estimations of statistical power derived from prior data or
expectations concerning progression. The sample size depends on (a) the
expected rate of progression in participants treated with placebo, (b) the
minimum size of drug effect judged to be clinically relevant, or rate of
progression expected in the active treatment arm(s), (c) the variation in
progression rate that occurs between participants, and (d) the precision of
the measurement technique. Despite results from older studies in persons
with knee OA suggesting rates of change for cartilage volume loss in
the range of 5−7% per year, more recent studies including from the
OAI have produced more conservative estimates in the range of 1−3%
per year with substantive variability. To date despite major advances
in measurement methods, structure-modifying efﬁcacy has not been
convincingly demonstrated for any of the existing pharmacologic agents.
Current trials have wanted for more responsive outcome measures both
for symptoms and structure in order to identify change.
Methods: Thus conservative study designs based on large x-ray and MRI
progression series currently in the public domain require large sample
sizes. If we could conﬁdently design studies based on smaller sample
sizes and/or shorter study durations, this would reduce the resource
implications for MRI based interventional studies.
Results: An increase in the study power could be gained by selecting
participants that have features that predict rapid progression in future
studies. Several studies have suggested that baseline clinical, biomarker
and imaging features are predictive of more rapid progression of cartilage
loss in the medial compartment of the knee. These include increased
body mass index (BMI), an increased level of type II collagen C-terminal
degradation products detected in the urine, the presence of varus mal-
alignment at the tibiofemoral joint, the presence on MRI of subchondral
bone marrow lesions or meniscal abnormalities.
Conclusions: These studies that stratify risk of OA progression will be
discussed along with their implications for screening failure rates in clinical
trials.
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Purpose: Clinical evidence of non-speciﬁc treatment effects, often termed
“placebo effect”, has been documented in a wide range of conditions.
Such non-speciﬁc beneﬁts could result from a patient’s response to
observation and assessment (Hawthorne effect), the administration of
a therapeutic treatment or ritual (placebo treatment), or the patient-
practitioner interaction. Randomised controlled trials (RCTs) to investigate
the beneﬁts of a treatment attempt to take into account such non-speciﬁc
effects by use of a placebo control. However, some investigators have
questioned whether the placebo effect exists at all, preferring to explain
improvements from baseline on placebo in terms of natural disease
remission or chance regression to the mean. Recently we undertook a
systematic review and meta-analysis of RCTs in OA to determine whether
there is evidence for placebo effects in OA and to examine potential
determinants of the size of such effects.
Methods: A systematic literature search was undertaken using Medline,
EMBASE, Scientiﬁc Citation Index, CINAHL and Cochrane Library. Ran-
domised placebo controlled trials in OA were included. The placebo effect
was estimated as the effect size (ES) – the standard mean difference
between baseline and endpoint. This was compared with the ES obtained
from untreated (observation) controls. ES for pain was the primary
outcome. Statistical pooling was undertaken as appropriate and 95%
conﬁdence interval (CI) was used for comparison. Quality of trials was
assessed and potential determinants of placebo effect were examined
using multiple regression analysis. Partial regression coefﬁcient (b) was
used to present the adjusted size of the association.
Results: We identiﬁed 198 trials with 193 placebo groups (16,364 pa-
tients) and 14 untreated control groups (1,167 patients) that met our inclu-
sion criteria. These included a range of therapies (non-pharmacological,
pharmacological and surgical treatments). The following results were
obtained:
1. Placebo was effective at relieving pain (ES=0.51, 95%CI 0.46, 0.55).
This effect was superior to untreated control (ES=0.03, 95%CI −0.13,
0.18), supporting placebo as a real entity.
2. Placebo also improved function (ES=0.49, 95%CI 0.44, 0.54) and
stiffness (ES=0.43, 95%CI 0.38, 0.49), but the highest ES was
for physician global assessment (ES=0.66, 95%CI 0.53, 0.78). No
improvements were seen for more objective measures such as quadri-
ceps strength, knee circumference or range of movement.
3. Placebo ES for pain relief was higher with treatments that had a
larger effect, perhaps reﬂecting greater expectancy of efﬁcacy from
the patient.
4. Placebo ES increased as baseline pain and sample size increased.
5. Route of delivery affected placebo ES for pain, with highest effects
seen when given by injection (higher with multiple than single injec-
tions), needling, and topical application.
6. Placebo ES for pain was highest for hand OA (0.80, 95%CI 0.65,
0.96), intermediate for knee OA (0.54, 95%CI 0.49, 0.6) and lowest
for hip OA (0.37, 95%CI 0.21, 0.53) perhaps implying that hip OA is
more severe disease and less amenable to non-speciﬁc effects.
Conclusions: Although regarded largely as a “nuisance” in RCTs, it is
apparent that non-speciﬁc effects of treatment in OA confer greater beneﬁt
in terms of symptom improvement than the effect derived from the more
speciﬁc effect of any one treatment. This has clear implications for design
of RCTs. More importantly, however, it emphasises the potential major
role for non-treatment effects in the medical care of people with OA and
should encourage us to investigate ways of optimising such beneﬁts.
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Purpose: Little is known about the natural course of deterioration of pain,
physical function or joint structure as a result of hip or knee osteoarthri-
tis. An international OARSI/OMERACT working group was created; the
objectives are to develop pain, physical function and structure states
that represent the progression from early to late disease for individuals
with OA of the hip and knee. These states are planned to be used as
a “hard endpoint” in potential disease-modifying drug trials, with some
states deﬁning “heoretical need for total joint replacement”.
Methods: New questionnaires were created to assess pain and functional
impairment. Structural assessments have been compared and structural
severity was deﬁned as joint space width loss on radiographs. A large
multicenter study is ongoing to assess these criteria.
Results:Work is ongoing. Current results will be presented at the OARSI
meeting.
Conclusions: The ﬁnal objective will be to combine the 3 domains (pain,
function and structure) and to create a composite index to deﬁne states
of severity and “theoretical need for total joint replacement” in hip/knee
osteoarthritis.
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Purpose: Therapeutic decisions in osteoarthritis (OA) often involve trade-
offs between accepting risks of side effects and gaining pain relief.
Previous studies suggested that the risk of side effects affected treat-
ment preferences but data on patients’ preferences for speciﬁc trade-offs
between pain relief and each side effect of treatment in OA are scarce.
Our objectives were (1) to determine patients’ maximum acceptable risk
increments (MARI) for different adverse effects from OA medication and
(2) to identify the predictors of these preferences.
Methods: Participants were individuals diagnosed with OA of the hip
or knee according to standard ACR criteria, age 45−74, able to under-
stand English and mentally competent. They were stratiﬁed into three
categories of disease severity – mild, moderate, and severe. MARI were
measured with a probabilistic threshold technique (TT). Risk and pain
levels in the TT scenarios were controlled for in a 2×2 randomized facto-
rial design. Clinical, sociodemographic, and psychological characteristics
(decisional conﬂict and locus of control) of the participants were assessed
using a self-administered questionnaire.
Results: 196 subjects participated in the study. For most side effects,
higher initial-risk levels in the TT tasks were associated with subjects’
reports that they would be willing to accept higher additional risks.
Depending on the initial level of risk and pain relief, mean MARI ranged
from 3% to 5% for heart attack/stroke, 5% to 8% for stomach bleed, 13%
to 21% for hypertension, 22% to 33% for ﬂuid retention, and 23% to 35%
